BIOLASE and Auris Surgical Robotics to Co-Develop Cataract-Removal
Letter of Commitment Seals Co-Development Relationship to Create
Best-in-Class Cataract Removal System for Use by Ophthalmologists
IRVINE, CA and REDWOOD CITY, CA -- (Marketwired) -- 10/15/13 --
BIOLASE, Inc. (NASDAQ: BIOL), the world's leading manufacturer and
distributor of dental lasers, and a pioneer in laser surgery in other
medical specialties, and Auris Surgical Robotics, Inc. ("Auris"), the
developer of a robotic microsurgical system designed specifically for
ophthalmic surgery, announced jointly today that they have signed a
letter of commitment to develop a new product for ophthalmologists.
The product is planned to feature BIOLASE's patented WaterLase YSGG
all-tissue atraumatic cutting technology mounted on a unique robotic
operating system manufactured by Auris.
"We evaluated a variety of advanced cutting technologies for use in
our robotic cataract-removal system," said Frederic Moll, M.D.,
Chairman and CEO of Auris. "For cutting precision, system
compatibility, and lack of tissue trauma, we found significant
advantages in using BIOLASE's Waterlase technology. We anticipate
that our system will have major advantages over traditional
phacoemulsification and should create a new standard for safety,
speed, and effectiveness in cataract removal."
The goal of the product in development is to improve the precision,
safety, and predictability of cataract-removal procedures, similar to
the way other telerobotic systems have enhanced therapeutic
effectiveness of procedures such as prostatectomy, fibroidectomy, and
knee hemi-arthroplasty. The development is in the feasibility and
"We believe the BIOLASE-Auris collaboration marks the beginning of a
wide adoption of WaterLase technology in ophthalmology," said
Federico Pignatelli, Chairman and CEO of BIOLASE. "It's also a good
example of the versatility of WaterLase technology in a non-dental
field. Our Occulase Division was created to focus our ophthalmology
resources for development, co-development, and licensing. We are
delighted that the first concrete agreement to result from this is
with a company founded and run by the founder of Intuitive Surgical,
Inc., our board member Fred Moll."
continued, "Robotics in medicine is gaining traction. This
is appearing in corporate decision-making, such as last week's
announced acquisition of Robotics company MAKO Surgical by Stryker
Corporation. Serendipitously, the co-founder of MAKO Surgical is the
Chairman and CEO of Auris Surgical Robotics, again Fred Moll, M.D."
About BIOLASE, Inc.
BIOLASE, Inc. is a biomedical company that
develops, manufactures, and markets innovative lasers in dentistry
and medicine and also markets and distributes high-end 2D and 3D
digital imaging equipment and CAD/CAM intraoral scanners; products
that are focused on technologies that advance the practice of
dentistry and medicine. The Company's proprietary laser products
incorporate approximately 340 patented and patent-pending
technologies designed to provide biologically clinically superior
performance with less pain and faster recovery times. Its innovative
products provide cutting-edge technology at competitive prices to
deliver the best results for dentists and patients. BIOLASE's
principal products are revolutionary dental laser systems that
perform a broad range of dental procedures, including cosmetic and
complex surgical applications, and a full line of dental imaging
equipment. BIOLASE has sold more than 23,000 lasers. Other laser
products under development address ophthalmology and other medical
and consumer markets.
For updates and information on WaterLase(R) and laser dentistry, find
BIOLASE online at www.biolase.com, Facebook at
www.facebook.com/biolase, Twitter at www.twitter.com/biolaseinc,
Pinterest at www.pinterest.com/biolase, LinkedIn at
www.linkedin.com/company/biolase, Instagram at
www.instagram.com/biolaseinc and YouTube at
BIOLASE(R) and WaterLase(R) are registered trademarks of BIOLASE,
About Auris Surgical Robotics, Inc.
Auris Surgical Robotics, Inc. is
a venture-funded company developing a robotic microsurgical system
designed specifically for ophthalmic surgery. Auris is the fourth
surgical robotics company founded by Frederic Moll, MD. Like the
other three, it is pursuing the use of robotics to provide
physicians, in this case ophthalmologists, with improved capabilities
to perform surgical procedures.
For further information, please contact:
Porter, LeVay & Rose, Inc.
Press spacebar to pause and continue. Press esc to stop.